Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Not yet recruiting	Phase 2	2025-09-03		NCT07151326

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chang Gung Memorial Hospital	214
China Medical University Hospital	112
Mackay Memorial Hospital	44
National Cheng-Kung University Hospital	83
National Health Research Institutes, Taiwan	52
National Taiwan University Hospital	540
Taichung Veterans General Hospital	63
Taipei Veterans General Hospital, Taiwan	80
Tri-Service General Hospital (TSGH)	36

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chang Gung Memorial Hospital (Lin-Kou),	Taoyuan	Taiwan	1
Chang-Gung Memorial Hospital, Kaohsiung	Kaohsiung City	Taiwan	2
China Medical University Hospital	Taichung	Taiwan	54
MacKay Memorial Hospital	Taipei	Taiwan	11
National Cheng-Kung University Hospital	Tainan	Taiwan	5
National Taiwan University Hospital	Taipei	Taiwan	174
Taichung Veterans General Hospital	Taichung	Taiwan	45
Taipei Veterans General Hospital	Taipei	Taiwan	64
Tri-Service General Hospital	Taipei	Taiwan	27